1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Lung Adenocarcinoma-Pipeline Insights, 2017

Lung Adenocarcinoma-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Lung Adenocarcinoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Lung Adenocarcinoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Lung Adenocarcinoma. DelveInsight’s Report also assesses the Lung Adenocarcinoma therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Lung Adenocarcinoma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Lung Adenocarcinoma-Pipeline Insights, 2017
Illustrative

- Lung Adenocarcinoma Overview
- Lung Adenocarcinoma Pipeline Therapeutics
- Lung Adenocarcinoma Therapeutics under Development by Companies
- Lung Adenocarcinoma Filed and Phase III Products
- Comparative Analysis
- Lung Adenocarcinoma Phase II Products
- Comparative Analysis
- Lung Adenocarcinoma Phase I and IND Filed Products
- Comparative Analysis
- Lung Adenocarcinoma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lung Adenocarcinoma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lung Adenocarcinoma - Discontinued Products
- Lung Adenocarcinoma - Dormant Products
- Companies Involved in Therapeutics Development for Lung Adenocarcinoma
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Lung Adenocarcinoma, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Lung Adenocarcinoma Assessment by Monotherapy Products
- Lung Adenocarcinoma Assessment by Combination Products
- Lung Adenocarcinoma Assessment by Route of Administration
- Lung Adenocarcinoma Assessment by Stage and Route of Administration
- Lung Adenocarcinoma Assessment by Molecule Type
- Lung Adenocarcinoma Assessment by Stage and Molecule Type
- Lung Adenocarcinoma Therapeutics - Discontinued Products
- Lung Adenocarcinoma Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Lung Adenocarcinoma, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Lung Adenocarcinoma Assessment by Monotherapy Products
- Lung Adenocarcinoma Assessment by Combination Products
- Lung Adenocarcinoma Assessment by Route of Administration
- Lung Adenocarcinoma Assessment by Stage and Route of Administration
- Lung Adenocarcinoma Assessment by Molecule Type
- Lung Adenocarcinoma Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...


Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Australia - Forecast

  • January 2017
    4 pages
  • Breast Cancer  

  • Australia  

View report >

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Lung Cancer Statistics in the UK

  • January 2017
    11 pages
  • Lung Cancer  

  • United Kingdom  

    Europe  

View report >

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.